ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology
Rabbit B Cell Select® Platform Yields Novel Antibodies for Studying Age-Related Mitochondrial Dysfunction
The study focuses on the development of antibodies that detect damaged mitochondria, which are more common as we age. ImmunoPrecise played a crucial role in this project by applying its proprietary rabbit B Cell Select™ platform to isolate and generate highly specific antibodies that target phosphorylated ubiquitin (p-S65-Ub), a marker of mitochondrial damage. These antibodies allow researchers to measure mitochondrial health, and the progression of damage related to aging.
Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies, commented: "The development of these novel recombinant p-S65-Ub antibodies represents a significant advancement in mitochondrial research. IPA’s proprietary high-precision tools not only enhance our understanding of PINK1-PRKN mediated signaling, but also show promising biomarker potential for various clinical applications. We are proud to have contributed to this groundbreaking research, which opens new avenues for studying mitochondrial dysfunction in aging and neurodegenerative diseases, and may lead to improved diagnostic, prognostic, and therapeutic approaches."
IPA is strategically positioned to capitalize on the booming anti-aging market, projected to reach
ImmunoPrecise's Contributions
ImmunoPrecise Antibodies (IPA) has made a significant contribution to this breakthrough study, showcasing yet another success from their proprietary rabbit B Cell Select™ platform. The Company's advanced antibody discovery process played a crucial role in the research. Utilizing the B Cell Select™ platform, IPA isolated specific immune cells from immunized rabbits. These cells were then meticulously screened to identify those producing antibodies highly specific to phosphorylated ubiquitin, a key indicator of mitochondrial damage. From the top-performing cells, IPA generated and validated recombinant antibodies, ensuring optimal sensitivity and accuracy in detecting damaged mitochondria. This achievement further demonstrates the power and versatility of IPA's rabbit B cell platform in producing high-quality, specific antibodies for cutting-edge research applications.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable
Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the Company’s Annual Report on Form 20-F for the year ended April 30, 2024 (which may be viewed on the Company’s SEDAR+ profile at www.sedarplus.ca and EDGAR profile at www.sec.gov/edgar). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. The Company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.
Source: ImmunoPrecise Antibodies Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241028151736/en/
Investor Relations
Kirsten Beduya
Quantum Media Group, LLC
kirsten@quantum-corp.com
Source: ImmunoPrecise Antibodies Ltd.